The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics
Top Cited Papers
Open Access
- 8 January 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 69 (5), 877-883
- https://doi.org/10.1093/cid/ciy1143
Abstract
Group A Streptococcus (GAS) infections result in a considerable underappreciated burden of acute and chronic disease globally. A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important World Health Organization (WHO) activity, influencing prioritization of investments. Here, the role, status, and directions in GAS vaccines research are discussed. WHO preferred product characteristics and a research and development technology roadmap, briefly presented, offer an actionable framework for vaccine development to regulatory and policy decision making, availability, and use. GAS vaccines should be considered for global prevention of the range of clinical manifestations and associated antibiotic use. Impediments related to antigen diversity, safety concerns, and the difficulty to establish vaccine efficacy against rheumatic heart disease are discussed. Demonstration of vaccine efficacy against pharyngitis and skin infections constitutes a key near-term strategic goal. Investments and collaborative partnerships to diversify and advance vaccine candidates are needed.Keywords
Funding Information
- Wellcome Trust
This publication has 32 references indexed in Scilit:
- Multi High-Throughput Approach for Highly Selective Identification of Vaccine Candidates: the Group A Streptococcus CaseMolecular & Cellular Proteomics, 2012
- Streptococcal skin infection and rheumatic heart diseaseCurrent Opinion in Infectious Diseases, 2012
- New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococciVaccine, 2011
- Non-prescription antimicrobial use worldwide: a systematic reviewThe Lancet Infectious Diseases, 2011
- Factors associated with Group A Streptococcus emm type diversification in a large urban setting in Brazil: a cross-sectional studyBMC Infectious Diseases, 2010
- Is Primary Prevention of Rheumatic Fever the Missing Link in the Control of Rheumatic Heart Disease in Africa?Circulation, 2009
- Epidemiology of Severe Streptococcus pyogenes Disease in EuropeJournal of Clinical Microbiology, 2008
- Pathogenesis of Group A Streptococcal InfectionsClinical Microbiology Reviews, 2000
- Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococciImmunology, 1996
- PERSISTENCE OF TYPE-SPECIFIC ANTIBODIES IN MAN FOLLOWING INFECTION WITH GROUP A STREPTOCOCCIThe Journal of Experimental Medicine, 1959